Skip to main content
. 2019 Feb 10;8(3):1103–1109. doi: 10.1002/cam4.2008

Table 3.

Cytostatic dose reductions in a study cohort

Total number of patients n (%) ARDI <80 n (%) ARDI 80‐90 n (%) ARDI >90 n (%)
ADM 27 (12.11) 20 (8.97) 6 (2.70) 1 (0.45)
CTX 2 (0.89) 2 (0.89) 0 (0.00) 0 (0.00)
VCR 4 (1.79) 2 (0.89) 1 (0.45) 1 (0.45)
Rituximab 18 (8.07) 15 (6.73) 2 (0.9) 1 (0.45)